Drug intelligence / Profile preview

hepalatide + pegylated interferon

Development stage: Unknown
Lead developer: Shanghai Hepu Pharmaceutical
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
Administration: Subcutaneous

Overview

Hepalatide + pegylated interferon is a combination drug used as a finite treatment for chronic hepatitis B. **Hepalatide (L47)** is a synthetic peptide (47 amino acids) targeting the liver, designed as an antiviral therapeutic for hepatitis B, administered subcutaneously. **Pegylated interferon alfa-2a** is a modified recombinant interferon that binds to human type 1 interferon receptors, activating the JAK/STAT pathway to stimulate the body's innate antiviral response. The combination aims to improve virologic response and maximize seroconversion rates for chronic hepatitis B, typically in patients stabilized on nucleos(t)ide analogues. Early data show promising safety and efficacy.[1][7]

Other names: hepalatide + pegylated interferonhepalatide（L47）+ pegylated interferon alfa-2a

Targets

NTCP (Na+-taurocholate cotransporting polypeptide)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)

Beyond the preview

Go deeper on hepalatide + pegylated interferon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hepalatide + pegylated interferon.